|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis for US Patent 7,364,736
What Are the Core Claims and Invention Scope of US Patent 7,364,736?
US Patent 7,364,736, issued on April 22, 2008, covers a method and apparatus related to the delivery of targeted therapeutic agents using a nanoparticle-based delivery system. The key claims focus on the composition of the nanoparticle, the method of delivering the therapeutic agent, and the targeting mechanism.
Main claims include:
- A nanoparticle comprising a biodegradable polymer encapsulating a therapeutic agent.
- Surface modifications that enable specific targeting to certain cell types.
- A method for delivering the nanoparticle to a subject, involving administering an effective dose via injection and achieving targeted delivery.
Scope:
The claims broadly cover polymer-based nanoparticles with specific surface modifications for targeted drug delivery, particularly relevant in oncology and other disease treatments requiring localized therapy.
How Do the Claims Position the Patent in the Current Nanoparticle Delivery Landscape?
The patent's claims establish a foundational framework for targeted nanoparticle delivery systems, emphasizing biodegradable polymers such as PLGA (polylactic-co-glycolic acid). The claims' breadth potentially cover variations in polymers, therapeutic agents, and targeting molecules, making the patent both influential and susceptible to challenges.
Comparison to existing key patents:
| Patent Number |
Focus Area |
Notable Features |
| US 6,365,179 |
Liposomal delivery systems |
Unrelated polymer focus |
| US 5,720,760 |
Nanoparticle targeting |
Emphasizes surface functionalization but differs in polymer use |
| US 5,932,268 |
Biodegradable polymer particles |
Similar polymer base; narrower claims |
| US 7,301,585 |
Targeting ligand in nanoparticle |
Specific targeting ligands, less general |
The '736 patent sits within a competitive space, overlapping particularly with patents around biodegradable polymers but distinguishes itself with its specific targeting mechanisms and delivery methods.
What Are Potential Challenges and Limitations for the Patent’s Validity?
Analyzing prior art reveals potential issues:
- Anticipation: Earlier patents like US 5,720,760 (1997) detail targeted nanoparticle systems with surface modification.
- Obviousness: Combining known biodegradable polymers with targeting ligands, as in US 5,932,268 (1998), and targeting methods from US 5,789,215 (1998), can render claims obvious.
- Enablement and Written Description: The patent provides sufficient disclosure for broad claims, but specific targeting mechanisms may not be fully detailed for all claimed embodiments.
Legal considerations:
- The patent's broad claims may face validity challenges based on prior art existing before 2006, the priority date.
- The scope for infringement analyses depends on the specific nanoparticle compositions and methods used by competitors, which often differ in surface ligands, polymers, or therapeutic agents.
How Has the Patent Been Cited and Used?
The patent has been cited in multiple later patents, especially in the field of targeted drug delivery, including:
- US 8,543,000: A nanoparticle system with targeted delivery for cancer therapy.
- US 9,425,918: Use of specific ligands for targeting in biodegradable nanoparticle systems.
- US 8,951,677: Advanced surface modification techniques for nanoparticles.
It also appears in licensing agreements and technology collaborations focusing on nanoparticle drug delivery systems.
Liability for infringement:
- Companies developing polymer-based targeted delivery systems with similar surface modifications should review for possible infringement.
- The patent’s expiration date in 2025 increases the landscape's exposure, allowing freedom to operate after that.
What Are Strategic Considerations for Stakeholders?
- For patent holders: Focus on enforcement against infringing products, especially those using targeted biodegradable nanoparticles.
- For competitors: Innovate beyond the claims, such as using non-Biodegradable polymers, different targeting molecules, or alternative delivery methods.
- For licensors/licensors: The patent's broad claims make it a valuable asset for licensing within nanoparticle drug delivery markets.
Key Takeaways
- US 7,364,736 covers a broad method of targeted nanoparticle delivery using biodegradable polymers, emphasizing surface modifications.
- The patent landscape indicates overlapping claims with prior biodegradable polymer and targeting ligand patents, impacting its defensibility.
- Its validity might be challenged based on prior art from the late 1990s to early 2000s, though its broad scope could withstand some legal scrutiny.
- The patent has been frequently cited, influencing subsequent nanoparticle delivery system patents, especially in cancer therapy.
- Expiration in 2025 will open opportunities for generic or equivalent innovations without infringing the patent.
FAQs
1. How does US 7,364,736 differ from earlier nanoparticle patents?
It emphasizes specific targeting surface modifications in biodegradable polymer nanoparticles, whereas earlier patents often focus on either one aspect or use different materials.
2. Are the claims of US 7,364,736 narrow or broad?
They are broadly drafted, covering various polymers, targeting ligands, and therapeutic agents, which raises both protection and validity considerations.
3. What legal challenges could the patent face?
Prior art references from the 1990s and early 2000s, particularly concerning targeting mechanisms and biodegradable polymers, might challenge its novelty or non-obviousness.
4. How does the patent impact current research?
It influences the development of targeted nanoparticle systems, particularly in oncology, and may limit alternative methods that fall within its claim scope.
5. When does the patent expire, and what does that mean for the market?
Expiration is expected in 2025, after which competitors can use the patented technologies without licensing.
References
- U.S. Patent and Trademark Office. (2008). Patent No. 7,364,736. Retrieved from [USPTO database].
- Smith, J. D., & Lee, A. H. (2010). "Nanoparticle Delivery Systems in Oncology," Journal of Drug Delivery, 15(4), 123-135.
- Wang, T., et al. (2012). "Advances in Targeted Nanoparticle Systems," Nanomedicine, 8(7), 1053-1065.
- Jones, P. R. (2015). "Patent Landscape Review: Targeted Drug Delivery," Intellectual Property Law Journal, 17(2), 89-105.
More… ↓
⤷ Start Trial
|
